Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer

被引:129
作者
Zhang, XP
Jin, TG
Yang, HM
DeWolf, WC
Khosravi-Far, R
Olumi, AF
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.1158/0008-5472.CAN-04-1498
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce apoptosis in a variety of tumorigenic and transformed cell lines but not in many normal cells. Hence, TRAIL has the potential to be an ideal cancer therapeutic agent with minimal cytotoxicity. FLICE inhibitory protein (c-FLIP) is an important regulator of TRAIL-induced apoptosis. Here, we show that persistent expression of c-FLIP(Long) [c-FLIP(L)] is inversely correlated with the ability of TRAIL to induce apoptosis in prostate cancer cells. In contrast to TRAIL-sensitive cells, TRAIL-resistant LNCaP and PC3-TR (a TRAIL-resistant subpopulation of PC3) cells showed increased e-FLIP(L) mRNA levels and maintained steady protein expression of c-FLIP(L) after treatment with TRAIL. Ectopic expression of c-FLIP(L) in TRAIL-sensitive PC3 cells changed their phenotype from TRAIL sensitive to TRAIL resistant. Conversely, silencing of c-FLIP(L) expression by small interfering RNA in PC3-TR cells reversed their phenotype from TRAIL resistant to TRAIL sensitive. Therefore, persistent expression of c-FLIP(L) is necessary and sufficient to regulate sensitivity to TRAIL-mediated apoptosis in prostate cancer cells.
引用
收藏
页码:7086 / 7091
页数:6
相关论文
共 51 条
[1]  
[Anonymous], 2003, The American College of Radiology Breast imaging reporting and data system atlas (BIRADS)
[2]  
Asakuma J, 2003, CANCER RES, V63, P1365
[3]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[4]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[5]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[6]   c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis [J].
Chang, DW ;
Xing, Z ;
Pan, Y ;
Algeciras-Schimnich, A ;
Barnhart, BC ;
Yaish-Ohad, S ;
Peter, ME ;
Yang, XL .
EMBO JOURNAL, 2002, 21 (14) :3704-3714
[7]   Proteases for cell suicide: Functions and regulation of caspases [J].
Chang, HY ;
Yang, XL .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2000, 64 (04) :821-+
[8]   Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway [J].
Chaudhary, PM ;
Eby, M ;
Jasmin, A ;
Bookwalter, A ;
Murray, J ;
Hood, L .
IMMUNITY, 1997, 7 (06) :821-830
[9]   RETRACTED: Suppression of NF-κB survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL (Retracted Article) [J].
Chawla-Sarkar, M ;
Bauer, JA ;
Lupica, JA ;
Morrison, BH ;
Tang, Z ;
Oates, RK ;
Almasan, A ;
DiDonato, JA ;
Borden, EC ;
Lindner, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (41) :39461-39469
[10]   Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].
Chinnaiyan, AM ;
Prasad, U ;
Shankar, S ;
Hamstra, DA ;
Shanaiah, M ;
Chenevert, TL ;
Ross, BD ;
Rehemtulla, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759